Sign In

Use the Qualified Clinical Data Registry (QCDR) to complete Merit-Based Incentive Payment System reporting.

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

Oncology Practice Insider

ASCO’s Oncology Practice Insider provides the latest news, information, and educational tools to assist with the successful management of oncology practice and the delivery of high quality patient care. OPI offers updates on ASCO programs, services, and cancer-related health policy, Medicare news, and billing and coding best practices. To sign up for the biweekly Oncology Practice Insider newsletter, please complete this form.

Date
Beginning August 2020, Medicare Administrative Contractors (MACs) resumed post-payment reviews of items and services with dates of service before March 2020. MACs may now begin conducting post-payment medical reviews for later dates of service. The Targeted Probe and Educate program (intensive education to assess provider compliance through up to 3 rounds of review) will restart later. The MACs will continue to offer detailed review decisions and education as appropriate.
On May 28, 2021, the Food and Drug Administration granted accelerated approval to sotorasib (Lumakras™, Amgen, Inc.), a RAS GTPase family inhibitor, for adult patients with KRAS G12C ‑mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA ‑approved test, who have received at least one prior systemic therapy. Read more. 
On May 28, 2021, the Food and Drug Administration granted accelerated approval to infigratinib (Truseltiq, QED Therapeutics, Inc.), a kinase inhibitor for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. Read more. 
On May 20, 2021, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) for patients with completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease who have received neoadjuvant chemoradiotherapy. Read more. 
ASCO invites interested stakeholders to submit comments on draft statements from the Telehealth: ASCO Standards now through Monday, May 10 at 11:59 PM (ET).
The Centers for Medicare & Medicaid Services Office of Minority Health (CMS OMH) will host a Building COVID-19 Vaccine Confidence webinar on Thursday, May 13 from 12:00 PM–1:00 PM (ET).
From April 12-16, U.S. members of ASCO participated in the 2021 ASCO Advocacy Summit, where 148 advocates from 44 states and the District of Columbia held 222 virtual meetings—the most ever held during an Advocacy Summit—with Members of Congress and staff to urge action on important policies to improve access to high-quality, equitable care for people with cancer.
ASCO is excited to announce the launch of a new project stemming from a collaboration between ASCO and the Association of Community Cancer Centers (ACCC) to address the lack of racial and ethnic diversity in cancer treatment trials. The goal of the collaboration is to develop practical strategies and solutions to increase clinical trial participation among people with cancer from racial and ethnic communities historically underrepresented in cancer treatment trials.